ストックスクリーナーアプリを入手
27.39
4.30%
1.13
プレマーケット:
28.79
1.40
+5.11%
前日終値:
$26.26
開ける：
$26.57
24時間の取引高:
682.76K
Relative Volume:
0.84
時価総額：
$2.59B
収益：
-
当期純損益:
$-115.88M
株価収益率:
-17.71
EPS:
-1.5468
ネットキャッシュフロー:
$-104.72M
1週間 パフォーマンス:
-0.47%
1か月 パフォーマンス:
-11.01%
6か月 パフォーマンス:
+28.23%
1年 パフォーマンス:
+110.05%
1日の値動き範囲:
$26.00
$27.50
1週間の範囲:
$26.00
$30.30
52週間の値動き範囲:
$13.10
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
EWTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
27.39 | 2.59B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Stifel initiates Edgewise Therapeutics stock with Hold rating, $30 target - MSN
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Increases By 8.9% - Defense World
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Rises By 8.9% - MarketBeat
Edgewise Therapeutics Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
JPMorgan Chase & Co. Boosts Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by JPMorgan Chase & Co. - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Down 6.1%Time to Sell? - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
December 19th Options Now Available For Edgewise Therapeutics (EWTX) - Nasdaq
How to Take Advantage of moves in (EWTX) - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Trading 7.4% HigherHere's What Happened - MarketBeat
Edgewise Therapeutics Advances Muscular Dystrophy Drug Sevasemten, Nears Pivotal Trial Milestone - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Average Rating of "Buy" by Analysts - MarketBeat
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 - BioSpace
Edgewise CEO to Present Pipeline Updates, 2025 Milestones at J.P. Morgan Healthcare Conference - StockTitan
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
How To Trade (EWTX) - Stock Traders Daily
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Insider Sells $2,737,000.00 in Stock - MarketBeat
Edgewise Therapeutics chief scientific officer sells $2.74 million in stock - Investing.com India
Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data (NASDAQ:EWTX) - Seeking Alpha
Franklin Resources Inc. Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Franklin Resources Inc. Acquires 20,674 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Marc Semigran Sells 29,709 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock - MarketBeat
Edgewise Therapeutics chief development officer sells $882,914 in stock By Investing.com - Investing.com Canada
Edgewise Therapeutics chief development officer sells $882,914 in stock - Investing.com
(EWTX) Technical Pivots with Risk Controls - Stock Traders Daily
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 2.5%Should You Sell? - MarketBeat
Barclays PLC Increases Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Geode Capital Management LLC Has $42.70 Million Position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Bought by Barclays PLC - MarketBeat
Edgewise Therapeutics Inc (NASDAQ: EWTX) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study - MSN
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Purchased by State Street Corp - MarketBeat
What is Leerink Partnrs’ Forecast for EWTX FY2026 Earnings? - Defense World
Leerink Partnrs Has Strong Estimate for EWTX FY2026 Earnings - MarketBeat
Short Interest in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Decreases By 10.2% - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Stock Price Expected to Rise, Evercore ISI Analyst Says - MarketBeat
EWTX Stock Rises On Upbeat Data From Rare Muscular Disorder Study - Barchart
Wellington Management Group LLP Sells 288,526 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease - AOL
Edgewise Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Edgewise Therapeutics (NASDAQ:EWTX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday - Benzinga
Edgewise weighs fast approval path for muscular dystrophy drug - BioPharma Dive
Edgewise Therapeutics (EWTX) Stock Jumps After Positive Trial News - Stocks Telegraph
Edgewise rises on mid-stage trial results for muscular dystrophy candidate - MSN
Edgewise Therapeutics Shares Higher on Positive Trial Results - MarketWatch
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):